Effect of Reducing the Dose of Stavudine on Body Composition, Bone Density, and Markers of Mitochondrial Toxicity in HIV-Infected Subjects: A Randomized, Controlled Study

McComsey, G. A.; Lo Re^III, V.; O'Riordan, M.; Walker, U. A.; Lebrecht, D.; Baron, E.; Mounzer, K.; Frank, I.
April 2008
Clinical Infectious Diseases;4/15/2008, Vol. 46 Issue 8, p1290
Academic Journal
Background. Stavudine is widely used in developing countries. Lipoatrophy and mitochondrial toxicity have been linked to stavudine use, but it is unclear whether switching to a lower dose can reduce these toxicities while maintaining human immunodeficiency virus (HIV) suppression. Methods. HIV-infected subjects receiving standard-dose stavudine with undetectable HIV type 1 RNA for ⩾6 months were randomized (ratio, 3:2) to receive one-half of the stavudine dose (switch arm) or to maintain the dose (continuation arm) while continuing to receive all other prescribed antiretrovirals. The following measurements were obtained at baseline and week 48: fasting lactate, pyruvate, and lipid levels; results of whole-body dual-energy X-ray absorptiometry; and mitochondrial DNA (mtDNA) measurements in fat and peripheral blood mononuclear cells. Change from baseline to week 48 was compared within and between groups. Results. Twenty-four patients (79% of whom were men and 79% of whom were African American; median age, 45 years) were enrolled in the study, 15 were enrolled in the switch arm, and 9 were enrolled in the continuation arm. The median duration of stavudine treatment was 55 months (range, 21-126 months). The median CD4 cell count was 558 cells/mm3 (range, 207-1698 cells/mm3). At baseline, the study arms had similar demographic characteristics and laboratory indices, except for body mass index, total lean body mass, and triglyceride levels (all of which were higher in the switch arm). Three patients (2 in the switch arm) discontinued the study because of study-unrelated reasons. CD4 cell counts remained unchanged. At 48 weeks, 6 patients (4 [27%] in the switch arm and 2 [22%] in the continuation arm) had detectable HIV RNA levels (median, 972 copies/mL; range, 60- 49,400 copies/mL). All patients with detectable HIV RNA levels reported significant lapses in treatment adherence; none exhibited mutations in HIV genotype. After the treatment switch, significant changes from study entry to week 48 were noted only for lactate level (median change, -0.27 mmol/L; range, -1.2 to 0.25 mmol/L; Pp .02) and fat mtDNA (median change, 40 copies/cell; range, -49 to 261 copies/cell; Pp.02). In the continuation arm, a significant loss of bone mineral density was seen at week 48 (median change, -1.7%; range, -6.3% to 0.8%; Pp.02). The only significant between-group difference was the change in bone mineral density from baseline (Pp.003). Conclusions. Reducing stavudine dose by one-half increased fat mtDNA and decreased lactate levels, suggesting improvement in mitochondrial indices while preserving HIV suppression in subjects who maintained adherence. A significant loss of bone mineral density was seen in patients receiving standard-dose stavudine but not in those receiving low-dose stavudine. These results suggest that switching to low-dose stavudine may improve mitochondrial indices while maintaining virological suppression.


Related Articles

  • The Effect of Reducing the Dose of Stavudine on Body Composition, Bone Density, and Markers of Mitochondrial Toxicity in HIV-Infected Subjects: Answers and Questions. Wanke, Christine // Clinical Infectious Diseases;4/15/2008, Vol. 46 Issue 8, p1297 

    The article highlights the study of McComsey on the effects of reducing dose of stavudine on body compositions, bone density and markers of mitochondrial toxity in (Human Immunodeficiency Virus) HIV-infected patients in the U.S. According to the author, the trial has been positive since the dose...

  • Translating Efficacy into Effectiveness in Antiretroviral Therapy. Fletcher, Courtney V. // Drugs;2007, Vol. 67 Issue 14, p1969 

    Durable and sustained suppression of HIV replication can be achieved as demonstrated in several recent clinical trials of antiretroviral (ARV) regimens. However, the efficacy demonstrated in the experimental setting does not always translate to effectiveness in the clinical setting. The...

  • Establishing ethical trials for treatment and prevention of AIDS in developing countries. Lo, Bernard; Bayer, Ronald // BMJ: British Medical Journal (International Edition);8/9/2003, Vol. 327 Issue 7410, p337 

    Developing countries have been hardest hit by HIV but often cannot afford the expensive drugs or high tech health care used in Western countries. How can researchers and sponsors of trials investigating treatment and prevention of HIV in developing countries make sure they take proper account of...

  • A Cluster Randomized Trial of Routine HIV-1 Viral Load Monitoring in Zambia: Study Design, Implementation, and Baseline Cohort Characteristics. Koethe, John R.; Westfall, Andrew O.; Luhanga, Dora K.; Clark, Gina M.; Goldman, Jason D.; Mulenga, Priscilla L.; Cantrell, Ronald A.; Chi, Benjamin H.; Zulu, Isaac; Saag, Michael S.; Stringer, Jeffrey S. A. // PLoS Clinical Trials;Mar2010, Vol. 7 Issue 3, Special section p1 

    Background:The benefit of routine HIV-1 viral load (VL) monitoring of patients on antiretroviral therapy (ART) in resource-constrained settings is uncertain because of the high costs associated with the test and the limited treatment options. We designed a cluster randomized controlled trial to...

  • Efficacy and Safety of Once-Daily Regimens in the Treatment of HIV Infection. Molina, Jean-Michel // Drugs;2008, Vol. 68 Issue 5, p567 

    Early versions of highly-active antiretroviral therapy (HAART) characteristically involved complicated combinations of different drugs, which were taken as varying numbers of pills and as multiple doses each day. With the recent availability of once-daily treatment drugs, simpler regimens are...

  • When the Nutritional Supplements Stop: Evidence from a Double-blinded, HIV Clinical Trial at Mengo Hospital, Kampala, Uganda. Namulema, Edith; Sparling, James; Foster, Harold D. // Journal of Orthomolecular Medicine;2008 3rd Quarter, Vol. 23 Issue 3, p130 

    The article reports on the study with regards to nutritional supplements as evidenced from a double-blinded clinical trial on Human immunodeficiency virus at Mengo Hospital in Kampala, Uganda. Result of the study shows that two nutrient mixtures taken for 52 weeks by HIV-positive patients who...

  • Mitochondrial DNA Haplogroups and Neurocognitive Impairment During HIV Infection. Hulgan, Todd; Samuels, David C.; Bush, William; Ellis, Ronald J.; Letendre, Scott L.; Heaton, Robert K.; Franklin, Donald R.; Straub, Peter; Murdock, Deborah G.; Clifford, David B.; Collier, Ann C.; Gelman, Benjamin B.; Marra, Christina M.; McArthur, Justin C.; McCutchan, J. Allen; Morgello, Susan; Simpson, David M.; Grant, Igor; Kallianpur, Asha R. // Clinical Infectious Diseases;11/1/2015, Vol. 61 Issue 9, p1476 

    Background: Neurocognitive impairment (NCI) remains an important complication in persons infected with human immunodeficiency virus (HIV). Ancestry-related mitochondrial DNA (mtDNA) haplogroups have been associated with outcomes of HIV infection and combination antiretroviral therapy (CART), and...

  • Mitochondrial Effects of HIV Infection on the Peripheral Blood Mononuclear Cells of HIV-Infected Patients Who Were Never Treated with Antiretrovirals. Miró, Òscar; López, Sònia; Martínez, Esteban; Pedrol, Enric; Milinkovic, Ana; Deig, Elisabeth; Garrabou, Glòria; Casademont, Jordi; Gatell, Josep M.; Cardellach, Francesc // Clinical Infectious Diseases;9/1/2004, Vol. 39 Issue 5, p710 

    To investigate the effects of HIV infection on mitochondrial DNA (mtDNA) content and other mitochondrial parameters, we used peripheral blood mononuclear cells (PBMCs) from 25 asymptomatic antiretroviral-naive human immunodeficiency virus (HIV)-infected patients and from 25 healthy control...

  • Strategies for Initiating Combination Antiretroviral Therapy. Michael L.#Tapper; Eric S.#Daar; Peter J.#Piliero; Kimberly#Smith; Corklin#Steinhart // AIDS Patient Care & STDs;Apr2005, Vol. 19 Issue 4, p224 

    Numerous potent antiretroviral regimens have proven successful as initial therapy in treat- ment-naïve HIV-infected patients. As the development of new agents makes possible new treatment regimens, providers are faced with increasingly complex questions of when to initiate treatment and which...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics